🔎 Trials Near Me

Akèy › Kasinòm epitelyal ovè › Oregon

Etid klinik pou Kasinòm epitelyal ovè nan Oregon

6 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan Oregon.

Vil nan Oregon

Tèks ofisyèl etid la (Anglè)

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
  • Compass Oncology - West - Tigard /ID# 275101, Tigard
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Providence Cancer Institute, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT06915025

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  • Research Site, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Legacy Medical Group Gynecologic Oncology, Portland
  • Providence Cancer Center Oncology, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • SCRI - Northwest Cancer Specialists, P.C., Portland
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.